

10/798372

CofS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Patent No. 6,911,464 B2

Issued: June 28, 2005

Inventors: Man *et al.*

Atty Docket No.: 501872-999098

Certificate
JUL 25 2005
of Correction

REQUEST FOR CERTIFICATE OF CORRECTION

ATTN: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Patentee hereby respectfully requests the issuance of a Certificate of Correction in connection with the above-identified patent. The correction is described below and on the attached Form PTO-1050.

In column 56, line 8 (part of claim 18), the term "thereof" at the end of the claim 18 was omitted. Also in claim 18, the term "diastereomers" was misspelled. In addition, the comma (" , ") between salt and solvate should be removed. Thus, claim 18 should read:

-- 18. A diastereomerically pure SS isomer of a compound of claim 1, substantially free of other diastereomers, or a pharmaceutically acceptable salt or solvate thereof.--

In column 56, lines 11-12 (part of claim 19), the term " , solvate, hydrate, stereoisomer, clathrate, or prodrug" should be replaced by the term "or solvate." Also in claim 19, the term "diastereomers" was misspelled. Thus, claim 19 should read:

-- 19. A diastereomerically pure RS isomer of a compound of claim 1, substantially free of other diastereomers, or a pharmaceutically acceptable salt or solvate thereof.--

In column 56, lines 16-17 (part of claim 20), the term " , solvate, hydrate, stereoisomer, clathrate, or prodrug" should be replaced by the term "or solvate." Also in claim 20, the term "diastereomers" was misspelled. Thus, claim 20 should read:

-- 20. A diastereomerically pure SR isomer of a compound of claim 1, substantially free of other diastereomers, or a pharmaceutically acceptable salt or solvate thereof.--

In column 56, lines 20-21 (part of claim 21), the term “, solvate, hydrate, stereoisomer, clathrate, or prodrug” should be replaced by the term “or solvate.” Also in claim 21, the term “diastereomers” was misspelled. Thus, claim 21 should read:


-- 21. A diastereomerically pure RR isomer of a compound of claim 1, substantially free of other diastereomers, or a pharmaceutically acceptable salt or solvate thereof.--

Marked-up revisions are shown in the attached Form PTO-1050.

A fee of \$ 100.00 is believed to be due for this Request. Please charge such fees, or any other required fees, to Jones Day Deposit Account No. 503013. Please issue a certificate of correction in due course.

Respectfully submitted,

Date: July 20, 2005



Hoon Choi (Limited Recog. No.)
JONES DAY
51 Louisiana Avenue, N.W.
Washington, DC 20001-2113
(202)-879-3939

For: Anthony M. Insogna (Reg. No. 35,203)
JONES DAY
12750 High Bluff Drive, Suite 300
San Diego, CA 92130
(858) 314-1200

Attachment

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 6,911,464 B2
 DATED : June 28, 2005
 INVENTOR(S) : Man *et al.*

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 56, claim 18, please revise as follows:

-- 18. A diastereomerically pure SS isomer of a compound of claim 1, substantially free of other ~~diastereomers~~ diastereomers, or a pharmaceutically acceptable salt, or solvate thereof.--

In column 56, claim 19, please revise as follows:

-- 19. A diastereomerically pure RS isomer of a compound of claim 1, substantially free of other ~~diastereomers~~ diastereomers, or a pharmaceutically acceptable salt, ~~solvate, hydrate, stereoisomer, clathrate, or prodrug~~ or solvate thereof. --

In column 56, claim 20, please revise as follows:

-- 20. A diastereomerically pure SR isomer of a compound of claim 1, substantially free of other ~~diastereomers~~ diastereomers, or a pharmaceutically acceptable salt, ~~solvate, hydrate, stereoisomer, clathrate, or prodrug~~ or solvate thereof. --

In column 56, claim 21, please revise as follows:

-- 21. A diastereomerically pure RR isomer of a compound of claim 1, substantially free of other ~~diastereomers~~ diastereomers, or a pharmaceutically acceptable salt, ~~solvate, hydrate, stereoisomer, clathrate, or prodrug~~ or solvate thereof. --

26 2005

MAILING ADDRESS OF SENDER:
 JONES DAY
 51 Louisiana Avenue, N.W.
 Washington, D.C. 20001-2113
 (202) 679-3939

PATENT NO. 6,911,464 B2

No. of add'l. copies
 @ 30¢ perpage